Compare ASTRAZENECA PHARMA with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs BIOCON - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA BIOCON ASTRAZENECA PHARMA/
BIOCON
 
P/E (TTM) x 116.1 32.8 353.6% View Chart
P/BV x 35.5 3.9 908.4% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   BIOCON
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
BIOCON
Mar-19
ASTRAZENECA PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,278707 180.7%   
Low Rs883554 159.4%   
Sales per share (Unadj.) Rs228.491.9 248.5%  
Earnings per share (Unadj.) Rs10.416.7 62.0%  
Cash flow per share (Unadj.) Rs16.324.2 67.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs98.8101.6 97.2%  
Shares outstanding (eoy) m25.00600.00 4.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.9 68.9%   
Avg P/E ratio x104.237.7 276.2%  
P/CF ratio (eoy) x66.426.1 254.7%  
Price / Book Value ratio x10.96.2 176.3%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m27,008378,330 7.1%   
No. of employees `0001.46.1 22.1%   
Total wages/salary Rs m1,53511,653 13.2%   
Avg. sales/employee Rs Th4,210.98,994.3 46.8%   
Avg. wages/employee Rs Th1,132.21,900.7 59.6%   
Avg. net profit/employee Rs Th191.11,635.3 11.7%   
INCOME DATA
Net Sales Rs m5,71055,144 10.4%  
Other income Rs m1231,444 8.5%   
Total revenues Rs m5,83356,588 10.3%   
Gross profit Rs m46315,883 2.9%  
Depreciation Rs m1474,478 3.3%   
Interest Rs m0709 0.0%   
Profit before tax Rs m43812,140 3.6%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,123 8.4%   
Profit after tax Rs m25910,026 2.6%  
Gross profit margin %8.128.8 28.1%  
Effective tax rate %40.817.5 233.6%   
Net profit margin %4.518.2 25.0%  
BALANCE SHEET DATA
Current assets Rs m3,20948,228 6.7%   
Current liabilities Rs m2,07030,376 6.8%   
Net working cap to sales %20.032.4 61.7%  
Current ratio x1.61.6 97.7%  
Inventory Days Days7268 105.9%  
Debtors Days Days3586 40.8%  
Net fixed assets Rs m79064,130 1.2%   
Share capital Rs m503,000 1.7%   
"Free" reserves Rs m2,41957,980 4.2%   
Net worth Rs m2,46960,980 4.0%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m4,605121,924 3.8%  
Interest coverage xNM18.1-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.5 274.1%   
Return on assets %5.68.8 63.9%  
Return on equity %10.516.4 63.8%  
Return on capital %17.716.8 105.9%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m30015,506 1.9%   
Fx outflow Rs m2,01510,399 19.4%   
Net fx Rs m-1,7155,107 -33.6%   
CASH FLOW
From Operations Rs m8811,546 0.8%  
From Investments Rs m-94-7,138 1.3%  
From Financial Activity Rs mNA-2,417 0.0%  
Net Cashflow Rs m-62,103 -0.3%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 15.7 10.7 146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   12,856 109,995 11.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 3, 2021 10:34 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS